Kolterman O G, Olefsky J M, Kurahara C, Taylor K
J Lab Clin Med. 1980 Sep;96(3):535-43.
In this study, we have evaluated one aspect of the cellular immune process--in vitro release of MIF by lymphocytes obtained from controls; well-controlled, ketosis-prone, insulin-dependent diabetic patients; nonketotic diabetic patients; and nonhyperglycemic obese patients. The results showed that MIF release by cells from well-controlled, insulin-dependent diabetic, nonketotic diabetic, and nonhyperglycemic obese subjects was 100% +/- 8, 48% +/- 17, and 36% +/- 17 of control values, respectively. Thus insulin-sensitive, ketosis-prone diabetic patients have normal MIf release while well-controlled on insulin therapy, whereas insulin-resistant, nonketotic diabetic and nonhyperglycemic obese patients have impaired MIF release. It is possible that this in vitro defect in a cellular immune process is related to the insulin-resistant state and that it may play a role in enhanced susceptibility to infection in insulin-resistant diabetic patients.
在本研究中，我们评估了细胞免疫过程的一个方面——从对照组、病情控制良好的酮症倾向胰岛素依赖型糖尿病患者、非酮症糖尿病患者以及非高血糖肥胖患者获取的淋巴细胞在体外释放巨噬细胞移动抑制因子（MIF）的情况。结果显示，病情控制良好的胰岛素依赖型糖尿病患者、非酮症糖尿病患者以及非高血糖肥胖受试者的细胞释放MIF量分别为对照值的100%±8、48%±17和36%±17。因此，胰岛素敏感的酮症倾向糖尿病患者在接受胰岛素治疗病情控制良好时MIF释放正常，而胰岛素抵抗的非酮症糖尿病患者和非高血糖肥胖患者的MIF释放受损。细胞免疫过程中的这种体外缺陷可能与胰岛素抵抗状态有关，并且可能在胰岛素抵抗糖尿病患者对感染易感性增加中起作用。
